Art. 1 Regulation (EU) 2024/1381

Subject matter

In forcesince 23 May 2024

This Regulation lays down detailed procedural rules for joint clinical assessments of medicinal products at Union level, as regards:

(a)

cooperation, in particular by exchange of information, with the European Medicines Agency on the preparation and update of joint clinical assessments of medicinal products;

(b)

interaction, including the timing thereof, with and between the Coordination Group established under Article 3 of Regulation (EU) 2021/2282, its subgroups and health technology developers, patients, clinical experts and other relevant experts during joint clinical assessments of medicinal products and their updates;

(c)

general procedural rules on the selection and consultation of stakeholder organisations and patients, clinical experts, and other relevant experts in joint clinical assessments at Union level;

(d)

the format and templates for dossiers with information, data, analyses and other evidence to be provided by health technology developers for joint clinical assessments;

(e)

the format and templates for joint clinical assessment reports and summary joint clinical assessment reports.